Vitamin K antagonist use in the elderly: special considerations

Authors: Siguret, Virginie; Pautas, Eric; Gouin-Thibault, Isabelle

Source: Future Cardiology, Volume 3, Number 3, May 2007 , pp. 321-330(10)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

As the population ages, the number of patients aged 75 years and over treated with vitamin K antagonists (VKAs) is steadily increasing. In this age group, the two main indications for oral anticoagulant therapy are the treatment of venous thromboembolic disease and the prevention of systemic embolism in patients with nonvalvular atrial fibrillation. In both indications, a target international normalized ratio of 2.5 (range: 2.0-3.0) is recommended. Although VKAs are beneficial in thromboembolic disorders, they are still underused. In this review, we will focus on two crucial topics in elderly patients, the specific management of VKAs in these patients and the hemorrhagic risk. Current recommendations concerning the management at the start of treatment, education and adequate monitoring may help to minimize the hemorrhagic risk in these frail patients.

Keywords: elderly; management; vitamin K antagonists; warfarin

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14796678.3.3.321

Publication date: 2007-05-01

More about this publication?

Future Cardiology reflects the new era of cardiology and highlights new molecular approaches in advancing cardiovascular therapy. The journal publishes clinical research, commentary and therapeutic overviews highlighting optimal therapy and future options and strategies.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites